The policy experts shaping Democrats’ drug-pricing approach - STAT

The policy experts shaping Democrats’ drug-pricing approach - STAT

More reads

• It’s just in mice! This scientist is calling out hype in science reporting. (STAT)
• Contract drug manufacturer Catalent to buy Paragon Bioservices in $1.2 billion deal. (Wall Street Journal)
• Hatteras launches new fund with $94 million for life science investments. (Xconomy)
• The health policy experts shaping Nancy Pelosi’s approach to drug pricing. (STAT Plus)